Lilly Commits Another $5.3bn To Tirzepatide Supply Expansion Effort

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Lilly is now spending about $9bn total to bring an Indiana manufacturing site for tirzepatide to readiness, although it is not expected to supply finished product until 2026.

Manufacturing
Lilly is increasing manufacturing spending driven by tirzepatide demand • Source: Shutterstock

Eli Lilly and Company is committing an additional $5.3bn to its ongoing efforts to ramp up manufacturing of tirzepatide, the blockbuster dual GLP-1/GIP agonist approved as Mounjaro for type 2 diabetes and Zepbound for obesity, at an in-development site in Indiana slated to produce its first doses in 2026 and continue scaling up production capacity into 2028. The multibillion-dollar expansion comes as the company and its competitor Novo Nordisk A/S continue to struggle to keep up with demand for weight loss-inducing medicines that far outstrips existing capacity to manufacture the products.

[Sidebar#SC150184]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Manufacturing

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 
• By Andrew McConaghie

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

With Mpox Vaccine In Serum Institute Pipeline, What Could Favor India Vaccine Makers?

 
• By Vibha Ravi

Serum Institute is working on an mpox vaccine while other Indian firms are weighing options after the WHO sounded an alert and a new case was reported in neighboring Pakistan. Scrip looks at factors that could favor development and/or manufacture of an mpox vaccine at Indian majors.

Manufacturing Snag For Myeloma Challenger Doesn’t Faze Regeneron

 
• By Andrew McConaghie

Linvoseltamab has missed out on an August US approval, but Regeneron remains confident it will emerge as the best-in-class BCMAxCD3 bispecific therapy.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.